Animal models have shown that overexpression of HDAC4 causes reduction of β-cell mass, and ongoing clinical trials are evaluating the utility of inhibitors and activators of HDACs in T2D therapy [48]. This evidence concerns the gene HDAC4 and type 2 diabetes mellitus.